CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.

It should be specifically noted that in the study of Park et al., the subgroup with lower tumor burden (blasts representing between 0 and 5% of bone marrow cells) had a higher CR rate and lower risk of CRS than the subgroup with a higher disease burden (≥ 5% bone marrow blasts or extramedullary disease), although these findings did not reach statistical significance.

also in 111,027 other papers